0.67
-0.0099(-1.45%)
Currency In USD
| Previous Close | 0.68 |
| Open | 0.68 |
| Day High | 0.7 |
| Day Low | 0.66 |
| 52-Week High | 1.99 |
| 52-Week Low | 0.45 |
| Volume | 464,691 |
| Average Volume | 225,821 |
| Market Cap | 50.67M |
| PE | -1.05 |
| EPS | -0.64 |
| Moving Average 50 Days | 0.7 |
| Moving Average 200 Days | 1.03 |
| Change | -0.01 |
If you invested $1000 in Cue Biopharma, Inc. (CUE) since IPO date, it would be worth $57.82 as of July 02, 2025 at a share price of $0.672. Whereas If you bought $1000 worth of Cue Biopharma, Inc. (CUE) shares 5 years ago, it would be worth $29.38 as of July 02, 2025 at a share price of $0.672.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cue Biopharma Provides Update on Most Advanced Clinical Stage Asset, CUE-101, Presented by Dr. Dimitrios Colevas at the DAVA 4th Hawaii Global Summit on Thoracic Malignancies
GlobeNewswire Inc.
Yesterday at 8:05 PM GMT
ORR of 50% in treatment-naïve patients with HPV+ R/M HNSCC12-month landmark survival of 88% and mOS of 32 months BOSTON, July 01, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a no
Cue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company’s Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the Treatment of Autoimmune Disease
GlobeNewswire Inc.
Jun 24, 2025 8:48 PM GMT
CUE-401, a first-in-class bispecific molecule designed to induce and expand Tregs in vivo through the co-activity of transforming TGF-β and a modified variant of IL-2BOSTON, June 24, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a cli
Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights
GlobeNewswire Inc.
May 12, 2025 8:05 PM GMT
Announced Boehringer Ingelheim strategic collaboration and license agreement for CUE-501, including an upfront payment of $12 million and ~$345 million in potential milestone payments Raised gross proceeds of ~$20 million in follow-on capital raise S